Understanding The Role of JAK Inhibition in Managing Myeloproliferative Neoplasms
This accredited symposium is designed to educate clinicians about how to proactively manage and prevent the most important side effects and treatment risks associated with JAK inhibitors, including cytopenias and thrombosis. Via a combined format of case discussion and didactic presentation, participants will learn the science behind JAK inhibitors and how this type of therapy differs from other available treatment options for myeloproliferative neoplasms. Learners will receive powerful information to proactively prevent and or manage side effects and other treatment risks by avoiding dose interruptions and/or reductions, monitoring patients receiving the therapy, and integrating risk stratification methods into their practice.
Looking for the Conference evaluations? Please click here to go to the main conference page.
Looking for the Workshop evaluations? Please click here to go to the workshop page.
- 1.25 ACPE
- 1.25 AMA PRA Category 1 Credit(s)™
- 1.25 Attendance
- 1.25 ANCC